Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | SCD | O00767 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 3/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.45 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.43 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 4/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22174245 | 0.90 | EGFR (0.43) | EPHX2FAAHSCDEGFRERBB2 | |
| SCHEMBL22174234 | 0.89 | BTK (0.46) | EPHX2SCDEGFRERBB2MGLL | |
| SCHEMBL22173959 | 0.88 | EPHX2 (0.59) | EPHX2FAAHEGFRERBB2TEAD1 | |
| SCHEMBL22174136 | 0.88 | NAAA (0.51) | EPHX2SCDEGFRERBB2TEAD1 | |
| SCHEMBL22174251 | 0.85 | EGFR (0.51) | EGFRERBB2BTK | |
| SCHEMBL22174226 | 0.83 | SLC6A2 (0.54) | SCDEGFRERBB2BTK | |
| SCHEMBL22174135 | 0.83 | EGFR (0.50) | EPHX2EGFRERBB2BTK | |
| SCHEMBL22446352 | 0.82 | EGFR (0.42) | EPHX2SCDEGFRERBB2BTK | |
| SCHEMBL22446327 | 0.80 | EPHX2 (0.51) | EPHX2EGFRTEAD1TEAD3BTK | |
| SCHEMBL22174129 | 0.78 | EPHX2 (0.47) | EPHX2EGFRERBB2TEAD1TEAD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771689-B2 | Cereblon modulators and uses thereof | VIVIDION THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20220298213-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | VIVIDION THERAPEUTICS, INC. | 2022-09-22 | — | — | US | disclosed |
| US-10869860-B2 | Cereblon modulators and uses thereof | VIVIDION THERAPEUTICS, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-10781239-B2 | In vivo engineered cereblon protein | VIVIDION THERAPEUTICS, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-20200216507-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | VIVIDION THERAPEUTICS, INC. | 2020-07-09 | — | — | US | disclosed |
| US-20200206201-A1 | CEREBLON MODULATORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298213-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | CRBN, CDR2, DCUN1D4 | EPHX2 2130/4885FAAH 4690/4885SCD 4300/4885 |
| US-20200216507-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | CRBN, CDR2, DCUN1D4 | EPHX2 2130/4885FAAH 4690/4885SCD 4300/4885 |
| US-11771689-B2 | Cereblon modulators and uses thereof | CRBN, CBFB, CNN2 | EPHX2 2655/4885FAAH 2667/4885SCD 4448/4885 |
| US-10869860-B2 | Cereblon modulators and uses thereof | CRBN, CBFB, CNN2 | EPHX2 2655/4885FAAH 2667/4885SCD 4448/4885 |
| US-20200206201-A1 | CEREBLON MODULATORS AND USES THEREOF | CRBN, CBFB, CNN2 | EPHX2 2655/4885FAAH 2667/4885SCD 4448/4885 |
| US-10781239-B2 | In vivo engineered cereblon protein | CRBN, CDR2, DCUN1D4 | EPHX2 2130/4885FAAH 4690/4885SCD 4300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.